• Zou H, Ge Y, Chen W, Yao D, Oi Lam Ung C, Lai Y, Hu H. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors. Int Immunopharmacol. 2024 May 10;132:111947. doi: 10.1016/j.intimp.2024.111947. Epub 2024 Mar 29. PMID: 38552296.
  • Lyu L., Feng Y., Huang B. Xu RH, Hu Y. Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials. Nat Biotechnol. 2024 Apr 17;42, 563–569). doi: 10.1038/s41587-024-02196-1. PMID: 38632441.
  • Zhang D, Lyu L, Han S, Xu J, Hu G, Zhao Q, Hu Y. Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials. Int Immunopharmacol. 2024 Jan 5;126:111273. doi: 10.1016/j.intimp.2023.111273. Epub 2023 Dec 4. PMID: 38041957.
  • Yang J, Yang J, Hu YJ. Characteristics of clinical trials of new oncology drugs approved in China. Cancer. 2023 Nov 20. doi: 10.1002/cncr.35106. Epub ahead of print. PMID: 37985356.
  • Shi J, Chen X, Hu H, Ung COL. Benchmarking drug regulatory systems for capacity building: an integrative review of tools, practice, and recommendations. Int J Health Policy Manag. 2023 Oct 16;2023;12:8100. doi:10.34172/ijhpm.2023.8100. PMID: 38618782.
  • Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. PLoS One. 2023 Oct 5;18(10):e0292239. doi: 10.1371/journal.pone.0292239. PMID: 37796814.
  • Shi J, Chen X, Hu H, Ung COL. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557. PMID: 37213606.
  • 時君楠, 陳獻文, 胡豪, 吳靄琳*. 推進藥品監管體系和監管能力現代化：藥品監管能力基準評估的國際經驗[J]. 中國食品藥品監管. 2023.04(231):14-33. doi: 10.3969/j.issn.1673-5390.2023.04.002
  • 姚東寧, 胡豪, 吳靄琳*. 澳門特别行政區藥品及醫療器械監管的發展與展望[J]. 中國食品藥品監管. 2021.12(215):16-25. doi: 10.3969/j.issn.1673-5390.2021.12.002
  • Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H, Ung COL. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model. Front Med (Lausanne). 2021 May 31;8:669509. doi: 10.3389/fmed.2021.669509. PMID: 34136505.
  • Liang Z, Lai Y, Li M, Shi J, Lei CI, Hu H, Ung COL. Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. Chin Med. 2021 Feb 16;16(1):23. doi: 10.1186/s13020-021-00433-2. PMID: 33593397.
  • 時君楠, 梁鑽姬, 賴雲鋒, 胡豪, 吳靄琳*. 發展和應用監管科學：中國、美國、歐盟和日本的藥品監管機構的經驗[J]. 中國食品藥品監管. 2020.5(196):38-55. doi: 10.3969/j.issn.1673-5390.2020.05